Download PDF
Thromb Haemost
DOI: 10.1055/a-2800-4026
Original Article

Pharmacodynamic interaction between emicizumab and coagulation Factor VIII

Authors

  • Matthias Chill

    1   Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany (Ringgold ID: RIN9177)

  • Emma Louise Konarski

    1   Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany (Ringgold ID: RIN9177)

  • Annika Klingberg

    1   Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany (Ringgold ID: RIN9177)

  • Birgitt Haarmeijer

    2   Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany (Ringgold ID: RIN9177)

  • Sonja Werwitzke

    3   Institute of Clinical Chemistry and Central Laboratory, Hannover Medical School, Hanover, Germany (Ringgold ID: RIN9177)

  • Andreas Tiede 

    2   Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany (Ringgold ID: RIN9177)
    3   Institute of Clinical Chemistry and Central Laboratory, Hannover Medical School, Hanover, Germany (Ringgold ID: RIN9177)

  • Olga Oleshko 

    1   Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany (Ringgold ID: RIN9177)
Further Information
 PDF Download

Emicizumab is a bispecific monoclonal antibody that mimics the cofactor function of activated factor (F) VIIIa, facilitating the FIXa-catalyzed activation of FX. Emicizumab binds to FIX/IXa and FX with considerably lower affinity than FVIIIa, suggesting that FVIII may outcompete emicizumab when present at higher concentrations. However, the interaction between emicizumab and FVIII at low FVIII concentrations is not well characterized. The current study aimed to assess the pharmacodynamic interaction between emicizumab and FVIII using classical pharmacological concepts of additivity and synergy. Thrombin generation was used as a surrogate marker of hemostatic capacity, providing well-defined quantitative outcome parameters. Tissue factor-triggered thrombin generation was measured in FVIII-deficient plasma supplemented with variable concentrations of emicizumab and recombinant FVIII, alone or in combination. A synergistic interaction between emicizumab and FVIII was observed, resulting in enhanced endogenous thrombin potential and peak thrombin generation beyond the levels expected from either agent alone. This synergistic effect was evident at low FVIII concentrations and was no longer observed once FVIII levels exceeded 20 IU/dl. These findings may provide a pharmacodynamic explanation for the pronounced hemostatic effect of emicizumab at low FVIII levels and offer a conceptual framework for evaluating synergistic interactions between novel non-factor therapies and intrinsic FVIII.



Publication History

Received: 04 December 2025

Accepted after revision: 28 January 2026

Accepted Manuscript online:
03 February 2026

© . Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany